Clinical Trial Update: Using the Optovue OCT to Select IOL Power

View source ↗

Summary

The trial evaluating use of Optovue OCT to select intraocular lens power for patients with Fuchs' endothelial corneal dystrophy and cataract was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Fuchs Endothelial Corneal Dystrophy

Snippet

Sponsor: Legacy Health System | Conditions: Fuchs' Endothelial Dystrophy, Cataract | Status: TERMINATED